BioPharma Dive December 16, 2024
Ned Pagliarulo

The Federal Trade Commission declined to challenge the deal before a deadline passed, allowing the companies to move ahead with the $16.5 billion acquisition.

Dive Brief:

  • Novo Holdings can complete its $16.5 billion acquisition of contract drug manufacturer Catalent after antitrust regulators in the U.S. declined to challenge the deal before the expiry of a deadline, the companies said Saturday.
  • The decision by the Federal Trade Commission, which had asked the companies for more details after the deal’s announcement in February, follows the European Commission’s approval of the acquisition earlier this month. Novo Holdings and Catalent said they now expect the transaction to close within the coming days.
  • As a result, Novo Nordisk, the Danish drugmaker that’s controlled by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Related Articles:
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article